| Literature DB >> 19678958 |
V Moises Serrano-Delgado1, Barbara Novello-Garza, Edith Valdez-Martinez.
Abstract
BACKGROUND: Umbilical cord banks are a central component, as umbilical cord tissue providers, in both medical treatment and scientific research with stem cells. But, whereas the creation of umbilical cord banks is seen as successful practice, it is perceived as a risky style of play by others. This article examines and discusses the ethical, medical and legal considerations that arise from the operation of umbilical cord banks in Mexico. DISCUSSION: A number of experts have stated that the use of umbilical cord goes beyond the mere utilization of human tissues for the purpose of treatment. This tissue is also used in research studies: genetic studies, studies to evaluate the effectiveness of new antibiotics, studies to identify new proteins, etc. Meanwhile, others claim that the law and other norms for the functioning of cord banks are not consistent and are poorly defined. Some of these critics point out that the confidentiality of donor information is handled differently in different places. The fact that private cord banks offer their services as "biological insurance" in order to obtain informed consent by promising the parents that the tissue that will be stored insures the health of their child in the future raises the issue of whether the consent is freely given or given under coercion. Another consideration that must be made in relation to privately owned cord banks has to do with the ownership of the stored umbilical cord.Entities:
Mesh:
Year: 2009 PMID: 19678958 PMCID: PMC2745420 DOI: 10.1186/1472-6939-10-12
Source DB: PubMed Journal: BMC Med Ethics ISSN: 1472-6939 Impact factor: 2.652
Some of the differences in the operation of Umbilical Cord Blood Banks in Mexico
| Private banks | Public banks |
|---|---|
| Assure compatibility in 100% of cases. | Compatibility reaches up to 90%. |
| The possibility of use by other members of the family of the donor is mentioned. This is an affirmation which is part of their marketing strategy. | A bioarchive of Histoleukocytic antigen is available to increase the possibility of compatibility. |
| The availability of the unit is immediate; however samples are regularly stored in foreign banks. | Availability is not immediate. A bioarchive assures better compatibility. |
| Storage costs are paid by the donor. On the average an initial payment of 800 USD is required as well as annual payments of 90 USD. Financial plans for 5, 10, 15 and even 20 years are available. | No cost to the donor; all costs are paid by the State. They promote solidarity through the altruistic donation of umbilical cords. Any person may obtain a sample for medical treatment without the need to pay. |
| No evidence that NOM-003-SSA2-1993 or quality certificate ISO 9001–2000 are being complied with; and no evidence of affiliation to international groups that would certify the adherence to quality standards. | Operation complies with international quality controls (World Association of Bone Marrow Transplants, International Foundation Netcord, American Association of Blood Banks AABB, Norma Oficial Mexicana NOM-003-SSA2-1993, Quality certifications ISO 9001–2000. |
| Despite the absence of certified quality control for the storage and transport of the samples, all umbilical cord samples are stored. | Strict quality controls for the selection of donors, the acquisition, storage, transport and cellular viability. Only samples that meet strict standards of quality and cellular viability are stored. |
| The acquisition of samples is usually completed by a third party; thereby the responsibility to complete this task in a prescribed manner is diluted. This also creates the possibility of clandestine payments to those who acquire the samples; this would bias the sample acquisition process in favor of the private banks. | Acquisition is completed by trained personnel. |
Indications for the transplant of haematopoietic stem cells
| Allogenic | Autologous |
|---|---|
| Congenital combined immunodeficiency | |
| Fanconi's medular aplasia | |
| Talasemia major | |
| Sickle cell | |
| Blackfan-Diamond's erythroblastopenia | |
| Kostmann's neutropenia | |
| Juvenile Osteopetrosis | |
| Thesaurismosis | |
| Chronic Granulomatous Disease | |
| Acute Leukemias | |
| Chronic Myeloid Lukemia | |
| Chronic Lymphocytic Leukemia | |
| Non-Hodkin Lymphoma | |
| Hodgkin Lymphoma | |
| Multiple Myeloma | |
| Histiocytosis | |
| Myelodysplastic Syndrome | |
| Solid Tumors | |
| Severe Marrow Aplasia | |
* No indication
Table adapted from: Asociación Mexicana de Medicina Transfusional, A.C., Agrupación Mexicana para el Estudio de la Hematología, A.C. Guía para el uso clínico de la sangre. México: Secretaría de Salud; 2007.